The pathogenesis of acute kidney impairment in patients with multiple myeloma
- PMID: 22920637
- DOI: 10.1053/j.ackd.2012.04.009
The pathogenesis of acute kidney impairment in patients with multiple myeloma
Abstract
Acute kidney injury in myeloma, a serious complication associated with poor prognosis, is generally mediated by the toxic and inflammatory effects of monoclonal free light chains (FLCs) on kidney proximal tubule cells and by the formation of intratubular casts through interaction with Tamm-Horsfall proteins. Production of excessive quantities of FLCs is seen in most cases of FLC-associated kidney injury, although a direct relation between quantity and nephrotoxicity does not exist, indicating variable toxicity among light chain species. Toxic effects of FLCs include inhibition of transport functions, Fanconi syndrome, generation of reactive oxygen species, cytoskeletal abnormalities, and apoptosis and necrosis in proximal tubule cells. Excessive endocytosis of FLCs in proximal tubule cells also induces cell stress responses that result in stimulation of inflammatory pathways through activation of nuclear transcription factors κB and mitogen-activated protein kinases, induction of proinflammatory cytokines, and epithelial to mesenchymal transition. The mechanisms of nephrotoxicity of FLC described here explain the basis of acute kidney injury seen in patients with multiple myeloma and provide the rationale for eliminating or reducing the FLC burden in myeloma patients with renal involvement. The inflammatory pathways that are activated as a result of FLC toxicity also show clearly how severe chronic tubulointerstitial nephritis can occur in patients with myeloma kidney and identify several attractive opportunities for novel therapeutic interventions.
Published by Elsevier Inc.
Similar articles
-
Proximal tubular injury in myeloma.Contrib Nephrol. 2007;153:87-104. doi: 10.1159/000096762. Contrib Nephrol. 2007. PMID: 17075225 Review.
-
The role of immunological assessment in patients with acute kidney injury and possible myeloma.Adv Chronic Kidney Dis. 2012 Sep;19(5):287-90. doi: 10.1053/j.ackd.2012.07.002. Adv Chronic Kidney Dis. 2012. PMID: 22920638 Review.
-
Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.BMC Nephrol. 2008 Sep 22;9:11. doi: 10.1186/1471-2369-9-11. BMC Nephrol. 2008. PMID: 18808676 Free PMC article.
-
Cytotoxicity of myeloma light chains in cultured human kidney proximal tubule cells.Am J Kidney Dis. 2000 Oct;36(4):735-44. doi: 10.1053/ajkd.2000.17620. Am J Kidney Dis. 2000. PMID: 11007675
-
Treatment of acute kidney injury with cast nephropathy.Clin Nephrol. 2014 Jul;82(1):1-6. doi: 10.5414/CN108293. Clin Nephrol. 2014. PMID: 24725380 Review.
Cited by
-
The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.Cell Immunol. 2019 Nov;345:103964. doi: 10.1016/j.cellimm.2019.103964. Epub 2019 Aug 13. Cell Immunol. 2019. PMID: 31492448 Free PMC article. Review.
-
Current Trends of Renal Impairment in Multiple Myeloma.Kidney Dis (Basel). 2016 Mar;1(4):241-57. doi: 10.1159/000442511. Epub 2016 Feb 3. Kidney Dis (Basel). 2016. PMID: 27536684 Free PMC article. Review.
-
Acute Kidney Injury: Medical Causes and Pathogenesis.J Clin Med. 2023 Jan 3;12(1):375. doi: 10.3390/jcm12010375. J Clin Med. 2023. PMID: 36615175 Free PMC article. Review.
-
Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Case Rep Nephrol. 2014;2014:940171. doi: 10.1155/2014/940171. Epub 2014 Jun 19. Case Rep Nephrol. 2014. PMID: 25045553 Free PMC article.
-
Free light chains injure proximal tubule cells through the STAT1/HMGB1/TLR axis.JCI Insight. 2020 Jul 23;5(14):e137191. doi: 10.1172/jci.insight.137191. JCI Insight. 2020. PMID: 32544092 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical